PHH:NASDAQ, Park Ha Biological Technology Co., Ltd.

PHH stock overview

Park Ha Biological Technology Co., Ltd. (PHH:NASDAQ) closed at $0.385 on October 27, 2025, down 0.08% on the day. The stock trades 99.1% below its 52-week high of $41.49 and 16.3% above its 52-week low of $0.331. Park Ha Biological Technology Co., Ltd. is part of the Consumer Non-Durables sector.

Key figures

Price
$0.385
Day change
-0.08%
Volume
428,938
Average volume
635,405
Market cap
13M+
52-week range
$0.331 – $41.49
50-day average
$0.451
200-day average
$8.36

Price action over the past year

In 252 trading sessions since October 22, 2025, PHH closed higher on 4 days (2%). Its best day was November 10, 2025 (+36.48%) and its worst was November 3, 2025 (-10.06%). The stock moved 10% or more in a single session 2 times. It opened at least 5% above the previous day's high 1 time.

About Park Ha Biological Technology Co., Ltd.

Park Ha Biological Technology specializes in providing skincare and cosmetic products under the brand name "Park Ha" in China. Our Operating Subsidiaries develop our proprietary beauty products and offer complimentary after-sales beauty services in our physical stores. Park Ha Jiangsu, in addition to operating our two physical stores, is the research and development center focusing on skincare products development and improvement for sensitive skin. Xinzhan leads the marketing and promotional efforts and is the entity in charge of our franchising business. Park Ha Shanghai is a training center for our franchisee staff. As part of our value-added service for our products, our directly operated and franchise stores offer "light beauty experience", a quick complimentary after-sales beauty services performed in the stores. Light beauty experience is offered to our customers as an effective way to demonstrate how our products are used in order to deliver best results.

Similar stocks

Find more stocks like PHH with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.